On Wednesday, leading independent equity research and corporate access firm SeeThruEquity announced that it has initiated coverage on Immune Therapeutics, Inc. (OTCQB: IMUN) with a 12-month price target of $0.61. IMUN is a specialty pharmaceutical company engaged in the manufacture, distribution and marketing of proprietary therapies targeting chronic, life-threatening diseases through the activation of the body’s immune system. The company’s technology platform includes two unique immunotherapies – Methionine-Enkephalin (MENK) and Low Dose Naltrexone (LDN), which is marketed as Lodonal™. MENK is a revolutionary option of therapy for those diagnosed with various forms of cancer, while LDN, which was originally developed as a treatment for individuals with opiate and alcohol dependence, now has the potential to become a primary drug used to treat a variety of autoimmune disorders, cancers and HIV/AIDS.
To view the full SeeThruEquity report, visit http://dtn.fm/q0yOP
Key highlights from the SeeThruEquity report include an update on IMUN’s progress toward marketing LDN in a large and relatively untouched market, results from the company’s phase I and II clinical trials studying MENK as an innovative solution to the treatment of various forms of cancer, successful enrollment and completion of clinical trials studying Lodonal in Nigeria and the potential impact of IMUN’s recently completed agreement with KRS Global for the further development and future profitability of the company.
“Immune Therapeutics, Inc. products and therapies are designed to exploit the intrinsic power of the immune system to help improve treatment of cancer, HIV/Aids, chronic inflammatory diseases, and autoimmune diseases,” Ajay Tandon, chief executive officer of SeeThruEquity, stated in yesterday’s news release.
SeeThruEquity’s coverage builds on what has been an exciting start to 2016 for IMUN shareholders. Last month, the company, alongside its partner organizations, achieved a major milestone in the development of Lodonal when it announced completion of its 90-day bridging trial comprised of HIV-positive patients. Following completion, IMUN submitted data to Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) in connection with the anticipated approval of Lodonal as an immune booster to improve the health and wellbeing of those affected by HIV-positive status and others with similarly compromised immune systems.
“September’s bridging trial enrollment completion and the efficiency of ensuing trials facilitated our submission of the results supporting the NAFDAC New Drug Application for Lodonal™,” Noreen Griffin, chief executive officer of IMUN, stated in a January news release. “It’s the objective of IMUN… to advance science and drug development with the intention of positively impacting patients with serious unmet healthcare needs.”
For more information, visit www.immunetherapeutics.com
